Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ester Del Signore

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Molecules (Basel, Switzerland)|June 27, 2025
HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs-A Long Way to the TopPamela Trillo Aliaga, Gianluca Spitaleri, Ilaria Attili, et al.
Frontiers in Oncology|August 29, 2022
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50Ilaria Attili, Carmine Valenza, Celeste Santoro, et al.
Genes|July 29, 2025
Management of MET-Driven Resistance to Osimertinib in <i>EGFR</i>-Mutant Non-Small Cell Lung CancerPanagiotis Agisilaos Angelopoulos, Antonio Passaro, Ilaria Attili, et al.
Genes|June 27, 2024
The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer TherapeuticsPamela Trillo Aliaga, Ester Del Signore, Valeria Fuorivia, et al.
Current Oncology (Toronto, Ont.)|September 27, 2024
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving ScenarioValeria Fuorivia, Ilaria Attili, Carla Corvaja, et al.
Therapeutic Advances in Medical Oncology|January 20, 2026
Actionable driver gene alterations in early-stage non-small cell lung cancer: a reviewIlaria Attili, Pasquale Pisapia, Gianluca Spitaleri, et al.
Cancers|July 13, 2024
Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 TrialsIlaria Attili, Valeria Fuorivia, Gianluca Spitaleri, et al.
American Journal of Clinical Oncology|February 18, 2011
Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trialFlavia Longo, Lucilla De Filippis, Andrea Zivi, et al.
Anticancer Research|January 2, 2020
Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective AnalysisLetizia Gianoncelli, Gianluca Spitaleri, Antonio Passaro, et al.
Frontiers in Oncology|May 12, 2020
Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO ModelFilippo de Marinis, Ilaria Attili, Stefania Morganti, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Molecules (Basel, Switzerland)|June 27, 2025
HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs-A Long Way to the TopPamela Trillo Aliaga, Gianluca Spitaleri, Ilaria Attili, et al.
Frontiers in Oncology|August 29, 2022
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50Ilaria Attili, Carmine Valenza, Celeste Santoro, et al.
Genes|July 29, 2025
Management of MET-Driven Resistance to Osimertinib in <i>EGFR</i>-Mutant Non-Small Cell Lung CancerPanagiotis Agisilaos Angelopoulos, Antonio Passaro, Ilaria Attili, et al.
Genes|June 27, 2024
The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer TherapeuticsPamela Trillo Aliaga, Ester Del Signore, Valeria Fuorivia, et al.
Current Oncology (Toronto, Ont.)|September 27, 2024
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving ScenarioValeria Fuorivia, Ilaria Attili, Carla Corvaja, et al.
Therapeutic Advances in Medical Oncology|January 20, 2026
Actionable driver gene alterations in early-stage non-small cell lung cancer: a reviewIlaria Attili, Pasquale Pisapia, Gianluca Spitaleri, et al.
Cancers|July 13, 2024
Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 TrialsIlaria Attili, Valeria Fuorivia, Gianluca Spitaleri, et al.
American Journal of Clinical Oncology|February 18, 2011
Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trialFlavia Longo, Lucilla De Filippis, Andrea Zivi, et al.
Anticancer Research|January 2, 2020
Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective AnalysisLetizia Gianoncelli, Gianluca Spitaleri, Antonio Passaro, et al.
Frontiers in Oncology|May 12, 2020
Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO ModelFilippo de Marinis, Ilaria Attili, Stefania Morganti, et al.
Pageof 4